To learn more, please call our Research Department at (513) 936-5388 or (888) 649-4800. Or email abradley@ohcmail.com or jmcguire@ohcmail.com
- Study number:
- UNK PRI 20 SCRI IIT
- Protocol title:
- A Phase II Study of Chemotherapy Based on Molecular Profiling Diagnosis for Patients with Carcinoma of Unknown Primary Site Provided: bevacizumab, erlotinib and molecular profiling assay
- Status:
- Open
|
| Study Number: |
UNK PRI 21 PXD101-CLN017 Topo Target |
| Protocol title: |
An Open-label, Randomized Phase II Trial of Belinostat (PXD101) in Combination with Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients with Previously Untreated Carcinoma of Unknown Primary |
| Status: |
Open |
-
-